This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

All News: More news

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Xerox Holdings Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - XRX 10:02pm NE
ROSEN, A RESPECTED AND LONGSTANDING FIRM, Encourages Zeta Global Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ZETA 09:56pm NE
Ant Group's President Han to become CEO in March; Jing to stay as chairman 09:26pm RE
University of Nebraska Wins the Abbott and Big Ten Conference's Nationwide 'We Give Blood Drive' Competition, Receives $1 Million Grant from Abbott 09:15pm PR
AIXI DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Xiao-I Corporation Investors to Secure Counsel Before Important December 16 Deadline in Securities Class Action - AIXI 09:13pm NE
Geron : Imetelstat Versus Best Available Therapy in Patients with Intermediate 2 or High Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized Open Label, Phase 3 Trial 09:07pm PU
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Light & Wonder, Inc. Investors to Inquire About Securities Class Action Investigation - LNW 08:56pm NE
Taiwan reports near doubling of Chinese warships nearby 08:54pm RE
Geron : Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion Dependent Patients with Erythropoiesis Stimulating Agent, Relapsed or Refractory/Ineligible Lower Risk Myelodysplastic Syndromes 08:25pm PU
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Unisys Corporation Investors to Inquire About Securities Class Action Investigation - UIS 08:23pm NE
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) 07:12pm AQ
Bells ring through Paris as Notre Dame re-opens its doors 07:11pm RE
US House to vote to provide $3 billion to remove Chinese telecoms equipment 07:07pm RE
Syrian rebels advance on Damascus 07:04pm RE
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab 07:01pm AQ
More news
  1. Stock Market
  2. Stock Market News
  3. Ezviz Network's Q1 Profit Jumps 37% as Revenue Climbs 15%; Shares Up 3%